GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

becotatug vedotin   Click here for help

GtoPdb Ligand ID: 14392

Synonyms: MRG-003 | MRG003 | Tsune Miyu® (China)
Approved drug
becotatug vedotin is an approved drug
Compound class: Antibody
Comment: Becotatug vedotin (MRG003) is a fully human anti-EGFR antibody-drug conjugate [5]. The payload is the synthetic antimitotic agent/tubulin polymerization inhibitor monomethyl auristatin E (MMAE). Becotatug vedotin was designed for potential antitumour activity.
No information available.
Summary of Clinical Use Click here for help
Becotatug vedotin (MRG003) was progressed through clinical trials to evaluate safety and efficacy as a treatment for advanced solid tumours. First approval was granted by China's NMPA in October 2025, to treat recurrent or metastatic nasopharyngeal cancer [1,3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06976190 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Phase 3 Interventional Shanghai Miracogen Inc.
NCT04868344 A Study of MRG003 in Patients With Advanced Solid Tumors Phase 1 Interventional Shanghai Miracogen Inc. 4
NCT05126719 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Phase 2 Interventional Shanghai Miracogen Inc. 2